One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for IgA Nephropathy. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on Povetacicept for IgA nephropathy by November 30, 2026, under a BLA from Vertex Pharmaceuticals.
What the FDA is deciding on Povetacicept for IgA nephropathy
The FDA is reviewing Vertex Pharmaceuticals' application to approve Povetacicept for IgA nephropathy.
Vertex seeks accelerated approval for adults with IgA nephropathy, with povetacicept given as an injection under the skin every 4 weeks. In a planned Week 36 interim analysis of the Phase 3 RAINIER trial, it lowered urine protein 49.8% more than placebo. Like Trutakna (atacicept), approved in July 2026, it blocks both BAFF and APRIL.
Would join a fast-growing IgAN treatment field that had zero targeted therapies before December 2021.
Who the Povetacicept decision matters to
IgA nephropathy is the most common primary glomerulonephritis worldwide, caused by abnormal IgA1 antibodies depositing in the kidney's mesangium, activating complement pathways and triggering inflammation that progressively damages the kidneys. While some patients have a benign course, about 1 in 5 people with IgA nephropathy develop kidney failure within 10 years (NIDDK).
Seven disease-specific therapies, including a gut-targeted steroid and drugs targeting complement, endothelin, and the APRIL/BAFF pathway have reached FDA approval since 2021, most recently Ultomiris (ravulizumab), whose accelerated approval AstraZeneca announced on October 21, 2026.
Prevalence: About 2 new cases per 100,000 people each year in the U.S., and an estimated 199,000 to 208,000 Americans were living with IgA nephropathy in 2021 (Otsuka-funded study, Clinical Nephrology, 2025). About 1 in 10 kidney biopsies in the U.S. show IgA nephropathy (NIDDK). Significantly more common in East Asian and Pacific Islander populations, with reported incidence up to 4 times higher. See our full IgA Nephropathy page for current treatments, recruiting trials, and community resources.
How Povetacicept works
Povetacicept: dual antagonist of BAFF and APRIL cytokines that broadly targets B-cell activation and pathogenic IgA production. Our full Povetacicept profile covers how it works, side effects in plain language, and its trial history.
What an approval or a rejection of Povetacicept would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where IgA Nephropathy treatment stands today
Read our full IgA Nephropathy treatment summary
IgA nephropathy treatment has transformed dramatically, with 7 disease-specific FDA-approved therapies now available: targeted-release budesonide (Tarpeyo), the endothelin blockers Filspari (sparsentan, which also blocks angiotensin) and Vanrafia (atrasentan), the complement inhibitors Fabhalta (iptacopan) and Ultomiris (ravulizumab), the APRIL inhibitor Voyxact (sibeprenlimab), and Trutakna (atacicept), approved in July 2026 as the first FDA-approved dual BAFF/APRIL inhibitor. Ultomiris is the newest, with accelerated approval announced by AstraZeneca on October 21, 2026.
Beyond the approved options, active trials include Biohaven's BHV-1400, a first-in-class degrader that selectively removes the pathogenic Gd-IgA1 antibody and whose pivotal trial is expected to start in the second half of 2026, plus late-stage programs like felzartamab, zigakibart and sefaxersen. Povetacicept is under FDA review, with a decision due November 30, 2026.
These targeted options represent a genuine shift from generic immunosuppression toward addressing the specific mechanisms of kidney damage. The IgA Nephropathy Foundation and NephCure maintain current trial databases.
If you have persistent protein in your urine above 0.5-1 gram per day despite maximum supportive therapy, you may qualify for trials of emerging therapies, and with multiple approved drugs now available, discussing the full treatment sequence with your nephrologist matters more than ever. A kidney biopsy is essential for diagnosis and helps predict your individual risk of progression.
The IgA Nephropathy page has every treatment and trial →Meanwhile, 93 IgA Nephropathy studies are open or about to open
Whatever the FDA decides here, research on IgA Nephropathy does not stop. The most recently updated:
Earlier-stage drugs Trial Friend tracks for IgA Nephropathy
We'll email you when the decision is public, with what it means in plain language, and when new trials open for IgA Nephropathy. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
When will the FDA decide on Povetacicept?
The FDA's target date (PDUFA date) for Povetacicept in IgA nephropathy is November 30, 2026.
Who disclosed it: Vertex Pharmaceuticals. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: Vertex press release
What is Povetacicept being reviewed for?
Vertex Pharmaceuticals submitted a BLA for Povetacicept in IgA nephropathy.
What to know: Vertex seeks accelerated approval for adults with IgA nephropathy, with povetacicept given as an injection under the skin every 4 weeks. In a planned Week 36 interim analysis of the Phase 3 RAINIER trial, it lowered urine protein 49.8% more than placebo. Like Trutakna (atacicept), approved in July 2026, it blocks both BAFF and APRIL. Would join a fast-growing IgAN treatment field that had zero targeted therapies before December 2021.
How it works: Dual antagonist of BAFF and APRIL cytokines that broadly targets B-cell activation and pathogenic IgA production.
More: the Povetacicept drug page explains it in plain language.
Is there already an FDA-approved treatment for IgA Nephropathy?
Yes. Trial Friend's drug list includes 7 FDA-approved drugs for IgA Nephropathy.
Approved: Tarpeyo (budesonide), Filspari (sparsentan), Fabhalta (iptacopan), Vanrafia (atrasentan), Voyxact (sibeprenlimab), Trutakna (atacicept), Ultomiris (ravulizumab).
Also coming: Felzartamab, Zigakibart, Sefaxersen.
Check: the IgA Nephropathy page also searches FDA drug labels for approved treatments.
What did the Povetacicept trials show?
The Phase 3 RAINIER trial randomized adults with biopsy-confirmed IgA nephropathy to povetacicept or placebo. In a planned Week 36 interim analysis of 199 patients, announced in March 2026, povetacicept lowered urine protein (UPCR) by 52.0% from baseline, 49.8% more than placebo.
More: the Povetacicept drug page has the full trial history and sources.
What are the side effects of Povetacicept?
In the RAINIER interim safety data from 557 patients treated for about 34 weeks on average, the most common side effects were upper respiratory infections (18.3% on povetacicept vs 11.4% on placebo) and injection site reactions (14.5% vs 2.2%), and every injection site reaction was mild or moderate. Serious side effects occurred in 3.0% of patients on povetacicept vs 4.3% on placebo, none were judged related to the drug, and there were no opportunistic infections.
More: the Povetacicept drug page has the safety details reported so far.
Can I get Povetacicept before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 93 IgA Nephropathy studies are open or about to open. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Vertex Pharmaceuticals directly. Registered programs are listed on ClinicalTrials.gov.
How much will Povetacicept cost?
Vertex Pharmaceuticals has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Povetacicept decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Vertex press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.